Lynk Pharmaceuticals
10:30 AM - 10:45 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
Lynk Pharmaceuticals, a clinical-stage company with global locations, actively seeks new partnerships to advance its innovative clinical programs in autoimmune and oncology indications. Co-founded by seasoned experts from Pfizer, Merck, and Johnson & Johnson, Lynk's primary focus is on developing therapies for autoimmune diseases and various cancers. With investments from prestigious institutions, Lynk has assembled an effective team and established a robust R&D pipeline, which includes 2nd and 3rd generation JAK inhibitors currently in multiple Phase I and II studies.
Lynk anticipates initiating 3 Phase III studies in 2023 and has formed commercialization partnerships with Simcere Pharmaceuticals in China. The company is also working closely with EQRx for the global development of LNK01001. Lynk has earned numerous awards and recognitions, emphasizing its dedication to innovation and highlighting its strong growth potential in the industry.
Lynk anticipates initiating 3 Phase III studies in 2023 and has formed commercialization partnerships with Simcere Pharmaceuticals in China. The company is also working closely with EQRx for the global development of LNK01001. Lynk has earned numerous awards and recognitions, emphasizing its dedication to innovation and highlighting its strong growth potential in the industry.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Zhejiang
Company HQ Country:
China
Year Founded:
2018
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
LNK01001
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
>4
Speaker
